title: Update of research on the role of EZH2 in cancer progression.
abstract: Accumulating evidence shows that enhancer of zeste homolog 2 (E2H2) is upregulated in a broad range of cancer types, such as breast cancer, prostate cancer, ovarian cancer, and colon cancer. Therefore, inhibiting EZH2 expression may be a promising strategy for anticancer therapy. This review focuses on the current understanding of the mechanisms underlying EZH2 regulation that are involved in cancer progression. Also, it introduces two EZH2 inhibitors that target EZH2 and could be potentially applied in the treatment of cancer in the future.
authors.affiliation: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, People's Republic of China.
authors.forename: Liang
authors.initials: L
authors.lastname: Shen
authors.forename: Jing
authors.initials: J
authors.lastname: Cui
authors.forename: Shumei
authors.initials: S
authors.lastname: Liang
authors.forename: Yingxin
authors.initials: Y
authors.lastname: Pang
authors.forename: Peishu
authors.initials: P
authors.lastname: Liu
keywords: EZH2; PRC2; cancer